Search

Displaying results 3881 - 3890 of 10000 in total
  1. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  2. Drug

    Oltipraz

    go.drugbank.com/drugs/DB12539
    Investigational

    Oltipraz has been used in trials studying the treatment and prevention of Lung Cancer, Liver Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  4. Drug

    AVN-944

    go.drugbank.com/drugs/DB05500
    Investigational

    AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism … AVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies.

  5. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

  6. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    A polyanionic compound with an unknown mechanism of action. … Suramin is manufactured by Bayer in Germany as Germanin®.

  7. Drug

    Salmon calcitonin

    go.drugbank.com/drugs/DB00017
    ApprovedInvestigational

    Synthetic peptide, 32 residues long formulated as a nasal spray.

  8. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [L12684] It was first described in the literature in 2001.[A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  9. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam is approved for use in Japan. … Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.

  10. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.